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Fisetin, a flavanol with anti-inflammatory, anti-cancer, and anti-aging properties, 
has shown promise for reducing fat accumulation in tissue culture and animal models. 
This plant sourced compound has limited studies supporting its effects on fat 
accumulation. Therefore, this study was completed to determine fisetin’s role in fat 
reduction along with its mechanism of action using Caenorhabditis elegans. C. elegans is 
a small roundworm with roughly 65% of its genes being conserved in humans related to 
disease. In this study, 100 and 200 µM fisetin has shown to reduce fat accumulation in 
wild-type worms. Body size, locomotion, and pumping rate were assessed in wild-type 
worms to determine if fisetin modified worm size, speed, and feed behavior, respectively. 
Mutant strains were tested to elucidate a potential pathway, of which tub-1 knockout 
mutants failed to reduce fat accumulation after fisetin treatment, suggesting this gene’s 
involvement. Gene expression of tub-1 was not altered by fisetin treatment, suggesting 
potential post-transcriptional regulation of fisetin. This study serves as an introduction to 
fisetin’s fat reducing effects via a tub-1 dependent mechanism.   
 
VI 




ACKNOWLEDGMENTS ................................................................................................ IV 
ABSTRACT ........................................................................................................................ V 
LIST OF TABLES .......................................................................................................... VIII 
LIST OF FIGURES .......................................................................................................... IX 
CHAPTER 
1. INTRODUCTION ...........................................................................................................1 
2. LITERATURE REVIEW ................................................................................................2 
2.1 Caenorhabditis elegans background ..................................................................2 
 
2.1.1 Introduction .........................................................................................2 
 
2.1.2 Life cycle. ...........................................................................................2 
 
2.1.3 Compound Intake ................................................................................4 
 
2.1.4 Locomotion .........................................................................................5 
 
2.1.5 Application of Caenorhabditis elegans in Life Science Research .....6 
 
2.2 Fisetin Background ............................................................................................7 
 
2.2.1 Introduction .........................................................................................7 
 
2.2.2 Anti-Inflammatory Effects of Fisetin..................................................7 
 
2.2.3 Anti-Cancer Effects of Fisetin ............................................................9 
 
2.2.4 Fisetin and Aging ..............................................................................11 
 
2.2.5 Effects of Fisetin on Fat Accumulation ............................................11 
 
2.2.6 Studies of Fisetin in Caenorhabditis elegans ...................................12 
 




3. METHODS AND MATERIALS ...................................................................................14 
 
3.1 Materials ..........................................................................................................14 
 
3.2 Maintenance and Preparation ...........................................................................14 
 
3.3 Triglycerid and Protein Quantification ............................................................15 
 
3.4 Pumping Rate, Locomotive Activity, and Body Size ......................................15 
 
3.5 Real-time PCR .................................................................................................16 
 
3.6 Statistical Analysis ...........................................................................................16 
 
4. RESULTS ......................................................................................................................19 
 
4.1 Fisetin Reduced Fat Accumulation ..................................................................17 
 
4.2 Fisetin's Effects on Body Size, Locomotion, and Pumping Rate ....................18 
 
4.3 Fisetin's Effects on Fat Accumulation in Mutatns ...........................................19 
 
4.4 Fisetin's Effects on Gene Expression ...............................................................22 
 
5. DISCUSSION ................................................................................................................24 
 
5.1 Discussion ........................................................................................................24 
 
5.2 Conclusion .......................................................................................................26 
 










































LIST OF FIGURES 
Figure Page 
 
Figure 2.1 Caenorhabditis elegans life cycle at 20°C ..........................................................4 
Figure 2.2 Structure of fisetin ..............................................................................................7 
Figure 4.1 Effects of fisetin on fat accumulation in C. elegans .........................................17 
Figure 4.2 Effects of fisetin C. elegans body size, locomotion, and pumping rate ...........19 
Figure 4.3 Effects of fisetin on fat accumulation in C. elegans mutants ...........................22 














Obesity is rapidly increasing in children and adults globally.1,2 The United States 
is one of the most obese populations, having more than 1/3 of its population being 
clinically obese at a rate that is steadily rising.3 Obesity has been linked to higher rates of 
diabetes and cardiovascular disease, therefore, there is great effort to find methods for 
reducing its prevalence.4-7 One such intervention would be using bioactive compounds 
with anti-obesity effects. For example, compounds such as cafestol, epigallocatechin-3-
gallate, and butein have shown to reduce fat accumulation in animal studies.8-10 
Fisetin is a flavanol found from several plants and fruits such as acacia trees, 
honey locust, strawberries, and grapes.11 The compound has shown to have anti-
inflammatory12-18, anti-cancer19-26, and anti-aging properties.27-30 However, research on 
the compound’s anti-obesity effects are limited.31-33  
Caenorhabditis elegans, a small, transparent nematode found in soil and 
decomposing matter, was the first organism to have its whole genome sequenced in 
1998.34,35 First proposed by Dr. Sydney Brenner in his scientific article The Genetics of 
Caenorhabditis elegans in 1974, the worm has been used as a staple in biological 
studies.35-38 C. elegans has shown to be an effective model in studying obesity, with up to 
65% of its genes being conserved in humans related to disease.37 The worm is not only 






2.1 Caenorhabditis elegans background 
2.1.1 Introduction 
C. elegans is a eukaryotic organism found in several geographical locations such 
as Northern Africa, North America, Asia, etc.39 Primarily found in soil and decomposed 
organic matter, the worm naturally consumes many species of bacteria. Among them, 
Escherichia coli OP50 is traditionally chosen as feed in laboratories for C. elegans. 
Nematode Growth Media (NGM), a media commonly used for C. elegans in laboratories, 
has limited quantities of uracil; and since E. Coli OP50 requires uracil for growth but 
cannot synthesize it, this strain is used as the standard diet for C. elegans.35,40-42 Growth 
temperature for C. elegans in laboratory settings ranges from 15°C - 25°C, depending on 
the desired rate of growth43, agreeing with their wild counterparts who predominate in 
temperate climates.44  
 
2.1.2 Life Cycle 
C. elegans has larval developmental stages (L1-L4) prior to adulthood, which can 
take up to 3 days’ time at 20°C (Fig. 1.1).45 C. elegans are unique in that they are either 
male (XO chromosome, roughly 0.1-0.2% of progeny) or hermaphrodites (XX 
chromosome), which can self-fertilize.46 Once the worm reaches the adult stage, eggs are 
laid for mainly 3 days in hermaphrodites or longer if through mating.46 C. elegans 
prodigies are genetically identical to their parent, and exhibit a total of 959 somatic cells 
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with 302 neurons in adult hermaphrodites. Adult males have an additional 79 neurons 
primarily for mating behavior.47  
Once eggs are laid, embryogenesis can take upwards of 16 hours at 20°C (Fig. 
1.1).46 The L1 to L2 stage can take ~16 hours and each stage following takes ~12 hours.46 
Between stages, the worm exhibits lethargus where a new cuticle forms and is shed 
through molting.46 The growth rate of each stage is temperature-dependent where 
marginal decreases in temperature (e.g. 15°C) delay growth and marginal increases in 
temperature exhibit accelerated growth (e.g. 25°C).45 If worms succumb to low food, 
inadequate temperatures, or environmental stresses (e.g. worm population density), they 
can transition to a dauer phase as early as their second molt.48 The dauer phase is a state 
of arrested development, which can be induced by pheromones, such as the potent 
ascaroside, (-)-6-(3,5-dihydroxy-6-methyltetrahydropyran-2-yloxy) heptanoic acid, as a 
result of the above-mentioned variables.48 The cuticle strengthens with alae, exterior 
pores close, specific gravity increases, pharyngeal pumping hinders, and movement 





Figure 2.1 Caenorhabditis elegans life cycle at 20°C. Information taken from Corsi et 
al.46  
 
2.1.3 Compound Intake 
C. elegans intakes compounds via the skin or pharynx using sensory cilia to 
register nutrient presence.51-55 The skin is covered by a tough exoskeleton known as the 
cuticle, roughly 0.5 μm thick and 80% collagen, which allows for the cylindrical shape of 
the animal.51,52 The ridged surface, referred to as the annulus, contains sublayers, 
including the cortical, medial, and basal membrane, followed by the hypodermis.51,52 The 
pharynx is a muscular tube totaling sixty-two cells, twenty of which encompass the 
pharyngeal nervous system, that uses rhythmic contractions to move ingested food along 
to the lumen for grinding.53 The cell makeup includes epithelial, gland, marginal, muscle, 
and neuron cells.53  Zheng et al.56 showcased the varied degrees in which researchers can 
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deliver various drugs to C. elegans in laboratory settings, called the NGM live and dead 
methods, using either live or dead E. coli OP50 after heating it for 30 minutes at 65°C.56 
This is because absorption efficiency may differ between the two methods as E. coli 
OP50 may consume the drug.56 Similarly, the liquid LB medium can use either live or 
dead E. coli OP50.56 Zheng et al.56 suggested that the delivery of compounds on the plate 
with dead E. coli OP50 serves both an economic advantage and minimizes the potential 
loss of compounds due to the metabolism of E. coli OP50.56 
 
2.1.4 Locomotion 
C. elegans moves via undulatory propulsion, similar to other nematodes.57,58 
Seventy-five motoneurons innervate the worms body wall muscles to allow for 
movement.59 Twenty-eight motoneurons innervate the neck and head, providing the 
ability for steering.59 Ninety-five body wall muscle cells, a pair on each side of the dorsal 
and ventral nerve cords, respectively, repeat from head to tail along the worm.59 They can 
crawl on solid surfaces or swim in aqueous solutions, producing short-waved and 
crescent-like body movements, respectively.60 Interestingly, confined spaces allow for 
greater swimming speeds of the worm due to its ability to utilize surrounding obstacles 
for propulsion.60 Pierce-Shimomura et al.61 showed that che-3 mutants, sensory deficient 
phenotype, exhibit lower bending frequencies when crawling and suddenly changes 
between swimming and crawling behaviors (as characterized by bending patterns) while 
in liquid media.61 Along with similar, yet less expressive changes in osm-3 mutants, 
which are sensory deficient, Pierce-Shimomura et al.61 believe C. elegans movement 
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behaviors are in part dictated by their ability to sense their surroundings as supported by 
the organism’s chemotaxis behavior.61,62  
 
2.1.5 Application of Caenorhabditis elegans in Life Science Research 
 C. elegans has shown to be an effective model in characterizing diseases, 
particularly diseases related to aging and obesity.37 With roughly 65% of C. elegans 
genes related to genes in human disease, the model exhibits a diverse and cost-effective 
way to perform disease analysis in a relatively short time.37 For example, C. elegans 
models have been developed to express human amyloid β or tau, which are peptides 
forming a plaque or a protein aggregate, respectively, which are characteristics of 
Alzheimer’s disease.38,63 In addition, C. elegans models expressing α-synuclein, which is 
believed to play a major role in dopamine metabolism and neurotransmission, has been 
developed to study Parkinon’s disease.38,64 Lastly, C. elegans has similar lipid 
metabolism and insulin signaling pathway to mammals, which makes this model effective 
to study obesity and diabetes related research.65 For example, C. elegans has conserved 
pathways for lipogenesis and fat oxidation, including sbp-1, fat-6, fat-7, and nhr-49.65 
The daf-2 gene, an ortholog to the insulin/insulin-like growth factor receptor in humans, 
plays a role in the production of fat and glycogen, where downstream targets such as daf-




2.2 Fisetin Background 
2.2.1 Introduction 
Fisetin (3,3',4',7-tetrahydroxyflavone, Fig. 2.2) is a yellow pigmented flavanol, a subclass 
of flavonoids66 found in several plant sources, such as strawberries (Fragaria sp.), 
cucumbers (Cucumis sp.), peach (Prunus sp.), honey locust (Gleditsia triacanthos), 
etc.11,67,68 Fisetin is found in cucumbers and tomatoes in amounts as low as 0.1 μg/g, 
while strawberries contain up to 160 μg/g.11,67-69 Similar to other flavanols, in vitro and in 
vivo model studies have shown fisetin to exhibit anti-inflammatory12-18, anti- cancer19-26, 
and anti-aging properties.27-30As obesity is known to be associated with underlying 
inflammatory responses, the anti-inflammatory effects of fisetin may also contribute its 
anti-obesity effects,70 although effects of fisetin on obesity are currently limited.31-33  
 
Figure 2.2 Structure of fisetin.  
 
2.2.2 Anti-Inflammatory Effects of Fisetin  
Similar to other flavanols, fisetin exhibits anti-inflammatory properties.71 Farsad-
Naeimi et al.12 explored fisetin’s effects on inflammatory markers in colorectal cancer 
using a double-blind, placebo-controlled study with 37 males averaging 55 years old for 
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one year.12 Fisetin significantly reduced plasma levels of interleukin-8 (IL-8), an 
inflammatory marker shown to contribute to tumor progression.12  
Yang et al.13 investigated fisetin’s effects on neuroinflammation due to lead 
contamination in mice.13 Both dosages of fisetin (25 and 50 mg/kg bodyweight) for four 
weeks reduced activation of nuclear factor kappa-light-chain-enhancer of activated B 
cells p65, tumor necrosis factor alpha (TNF-α), IL-6, toll-like receptor 4, and myeloid 
differentiation primary response 88; all well-known inflammatory markers in the brain.13  
Others similarly reported that pre-treatment with fisetin reduced gene expressions of 
TNF-α, IL-6, interleukin-1-β (IL-1β), and monocyte chemoattractant protein-1, as well as 
decreased protein expressions of TNF-α, IL-6, IL-1β, cyclooxygenase-2, inducible nitric 
oxide synthase, and high-mobility group protein 1 compared to lipopolysaccharide 
treated controls.14 Others have also shown reductions in TNF-α and IL-1β, inflammatory 
factors associated with atrial fibrillation (a risk maker associated with myocardial 
infarction) in Sprague-Dawley rats post-myocardial infarction, in male Wistar rats 
chronically exposed to cigarette smoke (also showing reductions in granulocyte 
macrophage colony-stimulating factor, IL-4, and IL-10), and in diabetic male Wistar rates 
(also showing reductions in IL-6).15-17 Huang et al.18 observed a reduction in several 
inflammatory cytokines, including IL-1β, TNF-α, IL-2, IL-4, IL-5, and IL-18, in asthma-
induced mice treated with fisetin, suggesting fisetin regulated airway 




2.2.3 Anti-Cancer Effects of Fisetin 
  Fisetin has shown anti-cancer effects in several types of cancers, including: 
bladder19, breast20, cervical21, colorectal22, leukemia23, lung24, pancreatic25, and skin26 
(Summarized in Table 2.1).  
Table 2.1 In vitro and In vivo studies on fisetin’s anti-cancer properties 
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a. topo I, type I topoisomerase; topo II, type II topoisomerase; BW, bodyweight 
b. AMPKα, AMP-activated protein kinase-alpha; ATF4, activating transcription factor 4; 
ATF6, activating transcription factor 6; Bax, BCL2 associated X; Bcl-2, B-cell 
lymphoma 2; CAT, catalase; eIF4E, eukaryotic translation initiation factor 4E; ERK1/2, 
Extracellular signal-regulated kinases 1/2; GPx, glutathione peroxidase; GR, glutathione 
reductase; GSH, glutathione; GST, glutathione-S-transferase; GβL, G-protein beta-
subunit-like protein; IκBα, nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor alpha; IKKα, inhibitor of nuclear factor kappa-B kinase subunit alpha; 
IKKβ, inhibitor of nuclear factor kappa-B kinase subunit beta; LC3B, light chain 3B; 
mTOR, mechanistic target of rapamycin; NFκB; nuclear factor kappa-light-chain-
enhancer of activated B cells; p-Akt, phosphorylated Akt; p-AMPK, phosphorylated 
activated protein kinase; PARP, poly (ADP-ribose) polymerase; PCNA, proliferating cell 
nuclear antigen; PERK, protein kinase R like endoplasmic reticulum kinase; p-ERK1/2, 
phosphorylated extracellular signal-regulated kinase 1/2; p-GSK-3β, phosphorylated 
glycogen synthase kinase-3 beta; p-H3; phosphorylated histone H3; PINK1, PTEN-
induced kinase 1; p-IκBα, phosphorylated nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor alpha; p-MEK1/2, phosphorylated dual specificity mitogen-
activated protein kinase kinase 1/2; p-PKC-α, phosphorylated protein kinase c alpha; p-
PRAS40, phosphorylated proline-rich Akt substrate of 40 kDja; p-p53, phosphorylated 
tumor protein p53; p-p70S6K, phosphorylated ribosomal S6 kinase; PTEN, phosphatase 
and tensin homolog; p21; cyclin-dependent kinase inhibitor 1; p53, tumor protein p53; 
p70S6K, ribosomal S6 kinase; SOD; super oxide dismutase; Vit. C, vitamin C; Vit. E, 




2.2.4 Fisetin and Aging 
Yousefzadeh et al.27 reported the effects of fisetin treatment lowered senescence-
associated markers, β-galactosidase (SA-β-gal) and p16Ink4a expressions, in mouse 
fibroblasts.27 This was further confirmed that fisetin treatment for 5 days reduced 
senescent cell count in white adipose tissue and p16Ink4a expression to similar levels of 
younger mice.27 SA-β-gal activity was also significantly reduced in the omental adipose 
tissue treated with 20 μM fisetin post-surgical removal for 48 hours.27 Others have also 
reported fisetin’s senescent reducing properties in vitro.28   
Currais et al.29 explored fisetin’s effects on behavior associated with aging. 
Animals treated with 500 mg fisetin/kg body weight for 7 months not only maintained 
their ability to relearn object location in the Barnes maze test, but also maintained short-
term recognition of familiar items in the recognition test compared to control animals.29 
Interestingly, it was also reported that protein associated with synaptic functions 
(activity-regulated cytoskeleton-associated protein, Homer, and synapse-associated 
protein 102) were preserved in older mice treated in fisetin.29 In addition, fisetin 
supplementation to improve spatial learning in older mice using the Morris water maze 
test, as well as reduce levels of malondialdehyde in the brain, showed a decline in 
oxidative stress in older mice.30 
 
2.2.5 Effects of Fisetin on Fat Accumulation 
Jung et al.31 showed that male C57BL/6J mice fed a high fat-diet and treated with 
0.5% (w/w) fisetin for 10 weeks experienced a significant reduction in body weight and 
both epididymal and retroperitoneal fat pad weights compared to the control.31 Similarly, 
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others reported that intraperitoneal injection of 20 mg fisetin treatment/kg body weight 
twice per week for 10 weeks significantly reduced body weight to 4.62±1.25 g compared 
to the control (9.55±1.38 g) in male C57BL/6J mice fed a high fat-diet.32 
Along with reduced body and adipose tissue weight, reduced adipocyte cell sizes 
with fisetin treatment were reported in in vivo animal studies.31-33 Consistently, a study 
reported that 50 μM fisetin significantly decreased preadipocyte differentiation in 3T3-L1 
preadipocytes.31 
As an underlying mechanism of fisetin on fat reduction, Jung et al.31 investigated 
fisetin’s impact on phosphorylation levels of mammalian target of rapamycin complex 
(mTORC1) and its target, ribosomal protein S6 kinase beta-1 (S6K1), both of which were 
down-regulated by fisetin.31 Others reported that treatment of fisetin was associated with 
decreased gene expression of peroxisome proliferator-activated receptor gamma 
(PPARγ), sterol regulatory element-binding protein 1 (SREBP1), fatty acid synthase 
(FAS), and stearoyl-CoA desaturase-1 (SCD1), and upregulated carnitine 
palmitoyltransferase I (CPTI), carnitine palmitoyltransferase II (CPT2), and cytochrome 
C oxidase subunit 8β (COX8β).33 Overall, these reports, although limited, support 
fisetin’s ability to reduce fat accumulation. 
 
2.2.6 Studies of Fisetin in Caenorhabditis elegans 
Two studies have explored fisetin’s effects in C. elegans.72,73 Kampkötter et al.72 
found that fisetin increased worm survivability under heat stress, decreased oxidative 
stress and lipofuscin, and increased localization of the daf-16 gene to the nucleus, which 
plays a critical role in several signaling pathways.72 Others reported that fisetin’s effects 
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survival and reproduction capacity with co-treatment of cyclophosphamide, a 
chemotherapy drug.73 Treatment of cyclophosphamide decreases C. elegans survivability 
(suggested to be due to its effects on attenuating immunity), while fisetin improved 
survivability and fertility.73 They further concluded that fisetin is involved with 
insulin/IGF-like signaling, as evident of the increased gene expression of egl-17 and 
attenuated daf-2 expression.73 This is further supported by others, egl-17 has shown to 
repress daf-2 receptors, thus allowing daf-16 activation and improving worm longevity 
under stress conditions.73,74  
 
2.3 Conclusion  
Bioactives found in natural food sources may serve as potent therapeutics for 
attenuating obesity. Fisetin, a natural flavanol found in several plant sources, has shown 
many beneficial effects including anti-inflammation, anti-cancer, and anti-aging. 
Although fisetin has exhibited anti-obesity properties, the studies are currently limited. 
Thus, we used C. elegans, a small yet powerful model for obesity research, to determine 




METHODS AND MATERIALS 
3.1 Materials 
Fisetin (purity >96.0%, batch: 6CZFM-CP) and 2′-deoxy-5-fluorouridine (FUDR) 
were purchased from TCI America (Portland, OR, USA). Infinity™ Triglycerides Liquid 
Stable Reagent was purchased from Fisher Diagnostics (Middletown, VA, USA). 
Pierce™ BCA Protein Assay Kit was purchased from Thermo Fisher Scientific 
(Middletown, VA, USA). Ampicillin was purchased from Sigma Aldrich Co. (St. Louis, 
MO, USA). Carbenicillin was purchased from Fisher Bioreagents (Pittsburgh, PA, USA). 
Other chemicals were purchased from Fisher Scientific (Pittsburgh, PA, USA). C. 
elegans wild-type (N2), C. elegans mutants (tub-1, nhr-49, sbp-1, sir-2.1, daf-12, daf-16, 
and daf-2), and E. coli OP50 were purchased from the Caenorhabditis Genetics Center 
(CGC, Minneapolis, MN, USA).  
 
3.2 Maintenance and Preparation  
C. elegans were maintained on NGM plates as previously described.8 Worms 
were fed as needed with live E. Coli OP50.42 To obtain a synchronized worm population, 
eggs were collected by dissolving collected gravid worms from NGM plates in a 
bleaching solution.37,42 After bleaching, worms were washed with M9 buffer and then S-
complete (both prepared as previously described75). L1 synchronized worms were fed 
with live E. coli OP50 until L4, where worms were washed of live E. coli OP50 with M9 
and S-complete, then transferred to a 12-well plate. From this, worms were fed dead E. 
coli OP50, heat killed for 30 minutes at 65°C56, with ampicillin (100 μg/mL) and 
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carbenicillin (50 μg/mL), as well as FUDR to prevent hatching of eggs.8 Once worms 
were grown to the adult stage, they were treated with fisetin. Fisetin was prepared at 100 
mM and 200 mM stock solution using dimethyl sulfoxide (≥99.9%, DMSO) as a vehicle. 
Adult nematodes were treated with 0.1% DMSO (control), 100 µM, or 200 µM fisetin as 
a final concentration. 
  
3.3 Triglyceride and Protein Quantification  
Post treatment, worms were transferred to centrifuge tubes. After washing worms 
with water five times, 0.05% Tween 20 was added and sonicated prior to triglyceride 
(TG) and protein quantification.8,76  TG was measured using Infinity™ Triglycerides 
Reagent with glycerol as a standard.8 Protein quantification was measured using Pierce™ 
BCA Protein Assay Kit with bovine serum albumin as a standard.8 Sample absorbances 
were measured at 510nm (triglyceride assay) or 562nm (protein assay) using a 
SpectraMax i3 microplate reader (Molecular Devices LLC, Sunnyvale, CA,USA) and 
SoftMax Pro 6 (version 6.5).  
 
3.4 Pumping Rate, Locomotive Assay, and Body Size 
 Pumping rate was measured by counting pharyngeal contractions of randomly 
selected worms for 30 seconds. Locomotive behavior and body size were measured using 
WormLab system (model MSCOP-002, MBF Bioscience, Willinston, VT, USA) and 
WormLab software (3.1.0 64-bit, MBF Bioscience, Williston, VT, USA). Worms were 
placed on low-peptone NGM plates with live E. coli OP50, then allowed to acclimate to 
the instrument’s light for 20 minutes prior to measurement. Videos were recorded for 1 
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minute, where width, length, and speed were measured using WormLab software (3.1.0 
64-bit, MBF Bioscience, Williston, VT, USA).8 
 
3.5 Real-time PCR 
 Real-time PCR was performed using TRIzol® (Thermo Fisher Scientific, Inc., 
Middletown, VA) for total RNA extraction, followed by cDNA reverse transcription by 
high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific, Inc., 
Middletown, VA) and thermal cycler (Bio-Rad Laboratories Inc., Hercules, CA).8,9 
StepOne Plus real-time PCR system (Applied Biosystems, Foster City, CA) was used for 
measuring gene expression. The following were used for TaqMan gene expression assays 
(Thermo Fisher Scientific, Inc., Middletown, VA): atgl-1 (Ce02406730_g1), cebp-2 
(Ce02421574_g1), hosl-1 (Ce02494529_m1), tub-1 (Ce02435686_m1), and ama-1 
(Ce02462726_m1) as an internal control. The delta-delta comparative threshold (Ct) 
method was used to analyze threshold values.8,9  
 
3.6 Statistical Analysis 
 Statistical analysis was performed using one-way or two-way analysis of variance 
(ANOVA), followed by the Tukey test using SAS Software (version 9.4.1, Cary, NC). 









4.1 Fisetin Reduced Fat Accumulation 
Wild-type C. elegans were treated for 48 hours after reaching the adult stage. 
Fisetin treated at 100 μM and 200 μM decreased triglyceride levels by 22% (p = 0.0004) 
and 39% (p < 0.0001) compared to the control, respectively (Fig. 4.1). 
 
Figure 4.1 Effects of fisetin on fat accumulation in C. elegans. Adult worms (N2 
Bristol, wild-type) were treated for 48 hours with 100 μM or 200 μM fisetin. Triglyceride 
levels were normalized by protein content. Data are means ± S.E (n = 8, taken from two 
independent experiments, each sample consisted of ~1,200 worms). Means with different 




4.2 Fisetin’s Effects on Body Size, Locomotion, and Pumping Rate 
Wild-type C. elegans were treated for 24 hours after reaching the adult stage. 
Fisetin induced no significant changes on the worms’ width compared to the control (Fig. 
4.2A). Fisetin (100 μM and 200 μM) did significantly reduce the worms’ length by 6% 
for both treatments (p= 0.0074 and p = 0.0108, respectively, Fig. 4.2B), which may be 
due to fisetin’s fat reducing effects (Fig. 4.1).8 To determine if fisetin impacted the 
worms’ energy expenditure, locomotive activity as movement speed was determined. 
Results showed no significant effect of fisetin on the worms’ speed compared to the 
control (Fig. 4.2C). Lastly, pharyngeal contractions were counted to determine if fisetin 
impacted the worms’ feeding behavior. No significant change by fisetin was seen in the 
worms’ pumping rate compared to the control, suggesting fisetin had no effect on food 




Figure 4.2 Effects of fisetin C. elegans body size, locomotion, and pumping rate. 
Adult worms (N2 Bristol, wild-type) were treated for 24 hours with 100 μM or 200 μM 
fisetin. (A) worm width , (B) worm length, (C) worm speed, (D) pharyngeal contractions 
counted for 30 seconds of randomly selected worms on low-peptone NGM plates. Data 
are means ± S.E (A-C: n = 67 – 70, D: n = 12; taken from two independent experiments). 
Means with different letters are significantly different at p < 0.05.  
 
4.3 Fisetin’s Effects on Fat Accumulation in Mutants 
TUB-1, a homolog of tubby proteins in humans, is involved in energy balance, 
particularly in fatty acid β-oxidation via kat-1.77,78 Thus, tub-1 mutants exhibit greater fat 
accumulation than wild-type worms along with deficiencies in chemotaxis and an 
extended lifespan.78 Results showed no significance on fat accumulation in tub-1 mutants 
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between treatment groups compared to the control, suggesting the tub-1 gene plays a 
significant role on fisetin’s fat lowering effects (Fig. 4.3).  
NHR-49, a homolog of peroxisome proliferator-activated receptor alpha, is 
involved in energy homeostasis and plays key a role in fatty acid β-oxidation.79,80 
Although there was no significant reduction in triglycerides with 100 μM fisetin, 200 μM 
fisetin significantly reduced fat accumulation by 31% (p = 0.0057) compared to the 
control (Fig. 4.3). This suggests that nhr-49 may not play key roles in the effects of 
fisetin’s fat reduction. 
SBP-1, a homolog of mammalian sterol regulatory element-binding protein, 
which is involved in lipogenesis.81 The sbp-1 mutants exhibit lower levels of fat 
accumulation.81 Fisetin treatment significantly reduced triglycerides by 17% with 100 μM 
fisetin (p = 0.0232) and by 34% with 200 μM fisetin (p < 0.0001) compared to the 
control, suggesting sbp-1 does not play a role in fisetin’s fat lowering effects (Fig. 4.3). 
 SIR-2.1, an ortholog to mammalian sirtuin, is involved in fat homeostasis.82-84 In 
addition, sir-2.1 is a key player in aging and longevity and interacts with daf-16 in the 
insulin/insulin-like growth factor-1 (IIS) pathway.82 Treatment with fisetin significantly 
reduced triglyceride contents by 21% at 100 μM fisetin (p = 0.0484) and by 35% with 
200 μM (p = 0.0024) compared to the control, suggesting sir-2.1 does not play a role in 
fisetin’s fat lowering effects (Fig. 4.3). 
DAF-2, a homolog to insulin/insulin-like growth factor receptor, is involved in 
energy homeostasis.8,85 DAF-16, an ortholog of mammalian Forkhead box O 
transcription factor, serves as a downstream target to daf-2 in the IIS signaling 
pathway.8,86 In daf-2 mutants, there was a significant reduction in triglycerides with 100 
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μM fisetin by 19% (p = 0.0069) and by 26% with 200 μM fisetin (p = 0.0004) compared 
to the control (Fig. 4.3). For daf-16, triglycerides were not significantly reduced by 100 
μM fisetin, but did show a significant reduction by 31% with 200 μM fisetin (P = 0.0012) 
compared to the control (Fig. 4.3). These results suggest both daf-2 and daf-16 do not 
play significant roles in fisetin’s fat lowering effects.  
DAF-12, a homolog to farnesoid X receptor, plays a role in fat metabolism and 
dauer development.87 Fisetin significantly reduced triglycerides by 28% with 100 μM (p 
= 0.0118) and by 44% with 200 μM (p = 0.0007) compared to the control, suggesting 





 Figure 4.3 Effects of fisetin on fat accumulation in C. elegans mutants. Adult were 
worms treated with 100 μM or 200 μM fisetin for 48 hours. Triglyceride levels were 
normalized by protein content. Data are means ± S.E (n = 4-8, taken from one to two 
independent experiments, each sample consisted of ~1,200 worms). Means with different 
letters at each variable are significantly different at p < 0.05.  
 
4.4 Fisetin’s Effects on Gene Expression 
 The tub-1 gene was chosen for real-time PCR based on the mutant study in Fig. 
4.3.  Interestingly, there was no significant difference on gene expression of tub-1 
between treatment groups (Fig. 4.4). 
 In addition to tub-1, other key genes involved in lipid metabolism were tested 
since these have no available mutants. CEBP-2, a homolog of CCAAT/enhancer-binding 
proteins, influences β-oxidation and fatty acid desaturation in C. elegans.88 No significant 
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difference between groups were observed for cebp-2, suggesting cebp-2 does not play a 
role in fisetin’s fat lowering effects (Fig. 4.4).  
 ATGL-1, a homolog of mammalian adipose triglyceride lipase, and the HOSL-1, 
an ortholog of hormone-sensitive lipase homolog, are lipases in C. elegans, which 
influence lipolysis.37,76 Relative gene expressions were not significantly different between 
all groups for both atgl-1 and hosl-1, suggesting neither genes play a role in fisetin’s fat 
lowering effects (Fig. 4.4). 
Figure 4.4 Effects of fisetin on fatty acid metabolism-related gene expression in C. 
elegans. Adult worms (N2 Bristol, wild-type) treated with 100 μM or 200 μM fisetin for 
48 hours. Gene expression was measured by real-time PCR. Data are means ± S.E (n = 3, 
each sample consisted of ~6,000 worms). Means with different letters at each variable are 





5.1 Discussion  
Fisetin, sourced from several plant sources11,67-69, has shown several health 
benefits in vitro and in vivo, yet studies on lipid metabolism are currently limited.12-30 
Thus, this study evaluated fisetin’s effects on lipid accumulation using C. elegans as a 
model system. Fisetin significantly reduced fat accumulation without affecting worm 
speed (representative of energy expenditure) or pumping rate (representative of food 
intake) in wild-type C. elegans. This effect of fisetin is mediated in part via tub-1, 
potentially by post-transcriptional regulation.  
Previously, it was reported that fisetin decreases lipogenic gene expressions 
(PPARγ, SREBP1, FAS, and SCD1) and increases fatty acid oxidation related genes 
(CPT1, CPT2, and COX8β) in high fat-diet fed mice.33 This is inconsistent with the 
current study showing no involvement of nhr-49, sbp-1, daf-2, nor daf-16 by fisetin on 
fat accumulation. The current study only suggests the involvement of tub-1, a gene 
related to β-oxidation,77,78 however, without increased gene expression of tub-1. Thus, it 
is possible that fisetin regulates tub-1 post-translationally. This can be determined by 
expressions of its downstream targets; ech-1.1, rbg-3 or rab-7. ech-1.1 is involved in 
fatty acid β-oxidation and increased expression reduces fat accumulation.8,79 
Alternatively, rbg-3, a RabGTPase-activating protein regulating fat storage homeostasis, 
is another downstream target of tub-1, and this may contribute to fisetin’s effect. This is 
supported by the report of rbg-3 RNAi decreased fat storage.89 Lastly, rab-7, both 
downstream of tub-1 and rbg-3, functions in chemotaxis and fat storage homeostasis.90 
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Both RBG-3 and its preferential target RAB-7 alter sensory molecules and neurons, 
which then play a role in regulating fat storage in C. elegans intestine.90 
There was a significant difference on fat accumulation between two fisetin 
treatments in tub-1 mutants without significance from the controls. It is possible that 
there are additional factors involved, such as kat-1, which encodes for 3-ketoacyl-coA 
thiolase and functions in β-oxidation synergistically with tub-1.91 It was suggested that 
kat-1 would compensate for defects in tub-1, even though both genes can be found in 
separate tissues, the intestines and neurons, respectively.78 We speculate that the dose 
required for fisetin to act on kat-1 may be greater, thus, higher a dose of fisetin (200 µM) 
were effective, but not lower a dose tested (100 µM) in the tub-1 mutant. Thus, the role 
kat-1 plays in fisetin’s fat lowering effects warrants further investigation.  
 There is currently no clear method to compare dosages in C. elegans to other 
mammals, such as humans. Thus, it is not clear how to interpolate the significance of 
concentrations used in current studies for humans. Fisetin consumption in humans has not 
been widely studied, with only one study reporting an average daily intake of 390 μg 
fisetin in 50 Japanese families.92 In the current study, 100 and 200 µM fisetin, roughly 
28.6 and 57.2 μg/mL, respectively, induced fat reduction in C. elegans. Other studies 
using phytochemicals with fat reducing properties have used higher concentrations than 
the following study in C. elegans.9,79 Similarly, other studies have used 100 µM fisetin on 
stress response in C. elegans, while another used 200 µM fisetin in human pancreatic 
duct cells with no impact on cell viability.25,72 Additionally, as much as 300 mg fisetin/kg 
body-weight was fed to mice resulting in a reduction in tumor growth.25 Future studies 
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would be needed to determine proper dose conversion from C. elegans to other animals 
and/or humans to properly interpret any observations from the current study. 
 
5.2 Conclusion  
 The current study investigated fisetin’s effects on fat metabolism in C. elegans. 
Fisetin reduced fat accumulation without affecting worm activity and pumping rate. The 
C. elegans tub-1 knockout mutant abolished the effects of fisetin on reduced fat 
accumulation, although no effects on tub-1 transcription levels were observed. These 
results suggest that fisetin reduces fat via the TUB-1 pathway, post-transcriptionally, 
leading to increased fatty acid β-oxidation. Additional studies are warranted to elucidate 







The current study provides support for fisetin’s fat reducing properties in C. 
elegans; fisetin reduces fat accumulation without altering locomotive activity or food 
intake rates. Although tub-1 is a potential target of fisetin’s fat lowering effect, gene 
expression did not support its regulation at the transcriptional level. To determine if 
fisetin’s effects are on post-transcriptional levels, known targets of tub-1 as well as  
mutants with TUB-1 bound to green fluorescence protein can be used to determine 
further how fisetin elicited its effects. Additionally, the role of kat-1 in the tub-1 mutant 
can clearly determine if kat-1 is also involved in fisetin’s fat lowering effects, especially 
at higher dosages.  
Lastly, several genes were tested in this study, yet C. elegans still has many 
pathways which need to be explored. A previous study has shown fisetin to attenuate fat 
accumulation via multiple pathways; among them, those that were not tested in the 
current study should be investigated in this model, such as the mTROC1 pathway, FAS, 
and SCD1.31,33 The mechanistic target of rapamycin (mTOR) encodes let-363 in C. 
elegans, which is involved energy homeostasis, while the fasn-1, homolog to FAS, and 
fat-6 and fat-7, orthologs to stearoyl-CoA desaturases, are involved in lipogenesis.8,78 
Additional targets of fisetin can be screened using the RNAseq method.  
This research can offer a starting point for understanding fisetin’s mechanism of 
lowering fat in C. elegans. Fisetin shows potential as an anti-obesity nutraceutical yet 
will still require human studies.  
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